Last reviewed · How we verify
Cis-UCA 2.5% emulsion cream
Cis-UCA 2.5% emulsion cream is a topical treatment that works by reducing inflammation and modulating the immune response.
Cis-UCA 2.5% emulsion cream is a topical treatment that works by reducing inflammation and modulating the immune response. Used for Treatment of mild to moderate psoriasis.
At a glance
| Generic name | Cis-UCA 2.5% emulsion cream |
|---|---|
| Also known as | Cis-UCA 2.5% |
| Sponsor | BioCis Pharma Ltd |
| Drug class | Topical anti-inflammatory |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 2 |
Mechanism of action
Cis-UCA is a derivative of cis-urocanic acid, which has been shown to have anti-inflammatory properties. When applied topically, it can help reduce inflammation and modulate the immune response, making it a potential treatment for various skin conditions.
Approved indications
- Treatment of mild to moderate psoriasis
Common side effects
- Skin irritation
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cis-UCA 2.5% emulsion cream CI brief — competitive landscape report
- Cis-UCA 2.5% emulsion cream updates RSS · CI watch RSS
- BioCis Pharma Ltd portfolio CI